Tau positron emission tomography imaging in tauopathies: The added hurdle of off‐target binding

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring - Tập 10 - Trang 232-236 - 2018
Laetitia Lemoine1, Antoine Leuzy1, Konstantinos Chiotis1, Elena Rodriguez-Vieitez1, Agneta Nordberg1,2
1Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
2Theme Aging, Karolinska University Hospital, Huddinge, Sweden

Tóm tắt

AbstractLigands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non‐Alzheimer's disease tauopathies. Several candidate compounds have been developed, showing good in vitro characteristics with respect to their ability to bind tau deposits; off‐target binding, however, has also been observed. In this short commentary, we briefly summarize the available in vivo and in vitro evidence pertaining to their off‐target binding and discuss the different approaches that are needed for the future development of tau positron emission tomography tracers.

Tài liệu tham khảo

10.1038/nrn2967 10.1002/ana.24546 10.1002/ana.24706 10.1097/00005072-199812000-00012 10.1186/s40478-016-0315-6 10.1002/ana.24844 10.1186/s13024-017-0162-3 10.1177/0271678X16683695 Chiotis K Stenkrona P Almkvist O Arakawa R Takano A Stepanov V et al. Head‐to‐Head In Vivo Comparison of Tau‐Specific PET Tracers in Alzheimer's Disease: [11C]THK5351 Vs [11C]PBB3 PET Imaging. Alzheimer's Association International Conference. London U.K.: Alzheimers Dement; 2017. p. P2–366. Jang J.K., 2017, Head to Head Comparison of [18F] AV‐1451 and [18F]THK5351 for Tau Imaging in Alzheimer's Disease and Frontotemporal Dementia, P4 Harada R., 2017, Correlations of 18F‐THK5351 PET with post‐mortem burden of tau and astrogliosis in Alzheimer's disease [published online ahead of print September 1, 2017], J Nucl Med 10.1186/s13195-017-0253-y 10.1016/S0197-4580(00)00100-7 Hansen A.K., 2017, MAO‐B inhibitors do not block in vivo Flortaucipir([(18)F]‐AV‐1451) binding [published online ahead of print November 10, 2017], Mol Imaging Biol 10.1002/mds.27013 Bevan‐Jones W.R., 2017, [18F]AV‐1451 binding in vivo mirrors the expected distribution of TDP‐43 pathology in the semantic variant of primary progressive aphasia [published online ahead of print September 14, 2017], J Neurol Neurosurg Psychiatry Lee H., 2017, [18F]‐THK5351 PET imaging in patients with semantic variant primary progressive aphasia, Alzheimer Dis Assoc Disord, 32, 62, 10.1097/WAD.0000000000000216 10.2967/jnumed.115.164848 10.3390/biom6010007 10.1016/j.jalz.2012.11.008 10.2967/jnumed.115.171678 10.1111/ene.13164 10.1212/WNL.0000000000003375 Ono M., 2017, Distinct binding of PET ligands PBB3 and AV‐1451 to tau fibril strains in neurodegenerative tauopathies, Brain, 140, 764 10.1038/srep45496 Ng K.P., 2017, In Vivo and in Vitro Demonstration of [18f]THK5351 Binding to Monoamine Oxidase–B in the Human Brain, P3 10.1002/mds.27271 10.1186/s13195-017-0325-z 10.1016/j.arr.2017.03.002 10.1016/j.neuron.2016.01.028 10.1093/brain/aww023 10.1002/ana.24711 10.1002/ana.25060 10.1038/nature23002
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Tập 10

232-236

Thông tin tác giả